Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Voyager Therapeutics Announced That The Joint Steering Committee With Its Collaborator Neurocrine Biosciences Has Selected A Lead Development Candidate In Friedreich's Ataxia Program. The Companies Expect The Program To Advance Into Human Trials In 2025

Author: Benzinga Newsdesk | February 26, 2024 08:12am

The candidate combines a frataxin (FXN) gene replacement payload with an intravenously administered, blood-brain barrier penetrant, novel capsid derived from Voyager's TRACER capsid discovery platform

Posted In: NBIX VYGR


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist